Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

755

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

Pimecrolimus Cream, 1%

DRUG

Elidel® (pimecrolimus) Cream

DRUG

Placebo of Pimecrolimus Cream, 1%

Trial Locations (27)

Unknown

Investigational Site 4, Hot Springs

Investigational Site 22, Little Rock

Investigational Site 20, Anaheim

Investigational Site 13, Fremont

Investigational Site 26, Norco

Investigational Site 17, Doral

Investigational Site 9, Hialeah

Investigational Site 16, Miami

Investigational Site 18, Miami

Investigational Site 19, Miami

Investigational Site 25, Miami

Investigational Site 8, Miami

Investigational Site 12, North Miami Beach

Investigational Site 3, Ormond Beach

Investigational Site 7, South Miami

Investigational Site 10, Tampa

Investigational Site 24, Tampa

Investigational Site 14, West Palm Beach

Investigational Site 1, Arlington Heights

Investigational Site 21, Lake Charles

Investigational Site 2, Silver Spring

Investigational Site 11, Saint Joseph

Investigational Site 27, East Windsor

Investigational Site 5, High Point

Investigational Site 23, Raleigh

Investigational Site 15, Cincinnati

Investigational Site 6, Nashville

All Listed Sponsors
lead

Glenmark Pharmaceuticals Ltd. India

INDUSTRY

NCT02896101 - Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter